Small conjugate-based theranostic agents:a tumour microenvironment responsive approach for cancer therapy

LU Xiaolin; ZHENG Ying; QIU Yang; ZHOU Xiang; LU Tao

doi:10.11665/j.issn.1000-5048.20160601

Journal of China Pharmaceutical University > 2016 > 47(6): 629-638. > DOI: 10.11665/j.issn.1000-5048.20160601

LU Xiaolin, ZHENG Ying, QIU Yang, ZHOU Xiang, LU Tao. Small conjugate-based theranostic agents:a tumour microenvironment responsive approach for cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(6): 629-638. DOI: 10.11665/j.issn.1000-5048.20160601

Citation:

PDF (2848 KB)

Small conjugate-based theranostic agents:a tumour microenvironment responsive approach for cancer therapy

More Information

Graphical Abstract

Abstract

Abstract

Theranostics, combining therapy and diagnosis, is an appealing approach for chemotherapy in medicine which exhibits improved biodistribution, selective cancer targeting ability, reduced toxicity, masked drug efficacy, and minimum side effects. The role of diagnosis tools in theranostics is to collect the information of the disease state before and after specific treatment. Currently, small conjugate-based systems have received much attention for cancer treatment and diagnosis. Relative to the normal tissues, tumor microenvironment shows great difference, including acidic excessive expression of various enzymes as well as low oxygen. In this review, the latest developments on small conjugate based theranostic agents for tumor treatment and diagnosis using fluorescence were summarized.
- tumour,
- theranostic agents,
- fluorescence,
- small-conjugate prodrug

FullText(HTML)

References (29)

References

[1]	Xie J,Lee S,Chen XY.Nanoparticle-based theranostic agents[J].Adv Drug Deliv Rev,2010,62(11):1064-1079.
[2]	Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy[J].Bioconjug Chem, 2011,22(10):1879-1903.
[3]	Nie S,Xing Y,Kim GJ,et al.Nanotechnology applications in cancer[J].Annu Rev Biomed Eng,2007,9(8):257-288.
[4]	Lim EK, Kim T, Paik S, et al. Nanomaterials for theranostics:recent advances and future challenges[J].Chem Rev,2015,115(1):327-394.
[5]	Jokerst JV,Gambhir SS.Molecular imaging with theranostic nanoparticles[J].Acc Chem Res,2011,44(10):1050-1060.
[6]	Dong X,Gu YQ.Application of optical molecular imaging technology in the diagnosis and treatment of diseases[J].J China Pharm Univ(中国药科大学学报),2014,45(2):145-152.
[7]	Zhou LZ,Wu XR,Chen L.Pharmacokinetics of magnetic nanoparticles as drug carrier and their applications in cancer diagnosis and therapy[J].J China Pharm Univ(中国药科大学学报),2003,34(3):279-282.
[8]	Sies H.Glutathione and its role in cellular functions[J].Free Radic Biol Med,1999,27(9/10):916-921.
[9]	Gregory RJ,Kirsten MT,McEwan J,et al.Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours[J].J Inorg Biochem,2004,98(10):1625-1633.
[10]	Santra S,Kaittanis C,Santiesteban OJ,et al.Cell-specific,activatable,and theranostic prodrug for dual-targeted cancer imaging and therapy[J].J Am Chem Soc,2011,133(41):16680-16688.
[11]	Yang Z,Lee JH,Jeon HM,et al.Folate-based near-infrared fluorescent theranostic gemcitabine delivery[J].J Am Chem Soc,2013,135(31):11657-11662.
[12]	Bildstein L,Dubernet C,Couvreur P.Prodrug-based intracellular delivery of anticancer agents[J].Adv Drug Deliv Rev,2011,63(1/2):3-23.
[13]	Maiti S,Park N,Han JH,et al.Gemcitabine-coumarin-biotin conjugates:a target specific theranostic anticancer prodrug[J].J Am Chem Soc,2013,135(11):4567-4572.
[14]	Bhuniya S,Lee MH,Jeon HM,et al.A fluorescence off-on reporter for real time monitoring of gemcitabine delivery to the cancer cells[J].Chem Commun,2013,49(64):7141-7143.
[15]	Kim T,Jeon HM,Le HT,et al.A biotin-guided fluorescent-peptide drug delivery system for cancer treatment[J].Chem Commun,2014,50(57):7690-7693.
[16]	Bhuniya S,Maiti S,Kim EJ,et al.An activatable theranostic for targeted cancer therapy and imaging[J].Angew Chem Int Ed,2014,53(17):4469-4474.
[17]	Vineberg JG,Zuniga ES,Kamath A,et al.Design,synthesis,and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy[J].J Med Chem,2014,57(13):5777-5791.
[18]	Vineberg JG, Wang T, Zuniga ES, et al. Design, synthesis, and biological evaluation of theranostic vitamin-linker-taxoid conjugates[J].J Med Chem,2015,58(5):2406-2416.
[19]	Lee MH,Kim JY,Han JH,et al.Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug[J].J Am Chem Soc,2012,134(30):12668-12674.
[20]	Dongbang S,Jeon HM,Lee MH,et al.Camptothecin delivery into hepatoma cell line by galactose-appended fluorescent drug deli-very system[J].RSC Adv,2014,4:18744-18748.
[21]	Wu X,Sun X,Guo Z,et al.In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug[J].J Am Chem Soc,2014,136(9):3579-3588.
[22]	Wu J,Huang R,Wang CC,et al.Thiol-inducible direct fluorescence monitoring of drug release[J].Org Biomol Chem,2013,11:580-585.
[23]	Dickinson BC,Chang CJ.Chemistry and biology of reactive oxygen species in signaling or stress responses[J].Nat Chem Biol,2011,7(8):504-511.
[24]	Lippert AR,Van de Bittner GC,Chang CJ.Boronate oxidation as a bioorthogonal reaction approach for studying the chemistry of hydrogen peroxide in living systems[J].Acc Chem Res,2011,44(9):793-804.
[25]	Kim EJ,Bhuniya S,Lee H,et al.An activatable prodrug for the treatment of metastatic tumors[J].J Am Chem Soc,2014,136(39):13888-13894.
[26]	Kumar R,Han J,Lim HJ,et al.Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug:in vivo imaging and precise cancer treatment[J].J Am Chem Soc,2014,136(51):17836-17843.
[27]	Manchun S,Dass CR,Sriamornsak P.Targeted therapy for cancer using pH- responsive nanocarrier systems[J].Life Sci,2012,90(11/12):381-387.
[28]	Song QL,Li P.Research progress of pH-sensitive material in pharmaceutical preparation[J].China J Hosp Pharm(中国医院药学杂志),2011,31:240-243.
[29]	Li SY,Liu LH,Jia HZ,et al.A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy[J].Chem Commun,2014,50(80):11852-11855.

Cited By

Get Citation

PDF

XML

Article views (894) PDF downloads (2501)

Turn off MathJax

Article Contents

Abstract

References

Small conjugate-based theranostic agents:a tumour microenvironment responsive approach for cancer therapy

Abstract

References

Catalog

Export File

Citation

Format

Content